Sandra Wiley Email & Phone Number

San Diego, Ca, Us

Providing nonclinical and clinical development consulting services with an emphasis on oncology translational science project management, asset evaluation, competitive intelligence, publication strategy, and KOL engagement.

San Diego, Ca, Us

MEI Pharma is a clinical stage oncology drug development company. Functioned as the sole PhD in biological sciences in the company. Reported to CMO.Provided scientific leadership in all aspects of MEI Pharma nonclinical and clinical translational development programs to advance pipeline of oncology therapeutics, including kinase and mitochondrial inhibitors as single agents and in combination with immunotherapy. Integral part of Clinical R&D efforts. Designed correlative biomarker studies for Phase I clinical trials in AML and CRC; managed contracts with KOLs and CROs to execute sample analysis; provided direct support to CRAs at trial sites. Reviewed and analyzed clinical trial data, aggregation of clinical and correlative data for presentations at SRC, SIV, BOD, and FDA meetings. Nonclinical and translational leader on novel formulation development team for mitochondrial clinical asset responsible for all IND-enabling nonclinical, DMPK, ADME, and toxicological studies.

San Diego, Ca, Us

Director of newly formed department reporting to the CMO.Responsible for all aspects of nonclinical and translational development to advance drug candidates from pre-IND to IND and NDA stage. Responsible for planning and executing nonclinical pharmacology and toxicology studies and clinical biomarker analysis. Supported Phase I-III clinical trials of kinase inhibitors and immunotherapy in heme malignancies. Authored materials for patent applications and submission to regulatory agencies. Selection and management of external CRO vendors and academic collaborations. Strategic support for executive leadership and new product development. Due diligence assessment of data for novel agents/assets to enable nomination of candidates for acquisition and development. Strategic intelligence for competitive landscape of drugs of interest to company.

San Diego, Ca, Us

Reported to VP Medical AffairsDirected nonclinical cancer studies across entire pipeline of small molecule drugs to enhance movement of assets in hematologic and solid tumor malignancies. Explored novel drug combinations and indications for company assets, including combinations with KRAS inhibitors.Integral part of Medical Affairs and Clinical Development teams supporting Phase I-III development of 2 kinase inhibitors in hematologic malignancies. Active member of Medical Affairs department leadership team and global corporate partnership leadership teams, product development teams, and 5 year strategic planning teams. Liaison with KOLs as subject matter expert and manager of preclinical IIS. Trained MSLs on MoAs; strategic conference coverage and reporting for internal stakeholders and company leadership. Designed clinical biomarker strategy for clinical trials.Science Communication: preparation of materials for conference booths, MSL field decks, submission to regulatory agencies, and corporate communications. Prepared and presented MoA and nonclinical data for Ad Boards, BOD, corporate alliance partners, and international scientific conferences. Invited speaker at Kinase Inhbitors and World RAS Summit conferences.

San Diego, Ca, Us

Developed and taught a course in Introductory Biochemistry to undergraduate and graduate students majoring in nutrition or kinesiology at the San Diego campus, in addition to an Introductory Biology course for computer science and engineering majors at the Tbilisi, Georgia campus.

San Diego, California, Us

Department of PharmacologyLed projects investigating the role of secretory pathway kinases and substrate phosphorylation in cancer cell and tumor microenvironment interactions in multiple cancers using in vitro and in vivo translational models. Strategic and operational role in securing over $1 million dollars in federal funds.

San Diego, California, Us

Spearheaded project identifying >100 new substrates for novel secretory pathway kinases that provided insight into the role of secretory pathway and extracellular phosphoproteins in cancer, heart disease, and rare biomineralization diseases. Cross-talk between cancer and stromal cells in the tumor microenvironment. Strategic and operational role in securing > $1 million dollars in federal grants.

San Diego, California, Us

Department of PharmacologyLiaison and project manager for corporate collaborations with large pharma, small clinical stage biotech, and biotech developing phosphorylation specific antibodies for research and diagnostic uses. Strategic and operational roles in securing > $1 million in corporate and federal grants. Research focus on signal transduction, secretory pathway kinases, and CISD (mitoNEET) proteins in metabolic diseases. Discovered and characterized CDGSH domain and CISD family proteins. Insights into redox and calcium signaling in ER and mitochondrial dysfunction in Wolfram Syndrome led to identification of potential therapeutics in drug screen. MOA of commercial and investigational diabetes drugs.

Tbilisi, N/A, Oo

General Biology (Biol100), developed and taught online and hybrid courses

San Diego, Ca, Us

Applied Biotechnology Program

San Diego, Ca, Us

Curriculum design and lab instruction inn Applied Biotechnology Certificate Program.

Mitokor was a discovery stage biotechnology company developing small molecule drugs to treat diseases characterized by mitochondrial dysfunction.Researched mitochondrial dysfunction in neurodegenerative diseases, type 2 diabetes, and osteoarthritis. Integral part of collaborative teams with large pharma and academic researchers. Assay development and drug screening / testing using in vitro and in vivo models.

Bachelor Of Arts (B.A.), Biochemistry And Cell Biology

Doctor Of Philosophy - Phd, Biological And Biomedical Sciences

Master Of Science (M.S.), Biochemical And Physiological Ecology